Q2 Earnings Forecast for Harrow Issued By William Blair

Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at William Blair issued their Q2 2025 earnings estimates for Harrow in a note issued to investors on Monday, July 14th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings of ($0.03) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's FY2025 earnings at $0.06 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%.

Other research analysts have also recently issued reports about the stock. BTIG Research started coverage on shares of Harrow in a research note on Thursday, June 12th. They issued a "buy" rating and a $62.00 target price on the stock. HC Wainwright upped their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th. B. Riley dropped their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harrow currently has an average rating of "Buy" and an average price target of $63.83.

Harrow Stock Performance

HROW traded down $0.25 during midday trading on Wednesday, reaching $35.89. The company had a trading volume of 482,017 shares, compared to its average volume of 500,180. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91. The stock has a market cap of $1.32 billion, a PE ratio of -64.09 and a beta of 0.41. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The business has a 50-day moving average price of $30.13 and a two-hundred day moving average price of $28.87.

Institutional Trading of Harrow

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in shares of Harrow in the 4th quarter worth $25,000. Quarry LP bought a new position in shares of Harrow in the 1st quarter worth $32,000. Tower Research Capital LLC TRC increased its holdings in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Harrow in the fourth quarter valued at $78,000. Finally, AlphaQuest LLC raised its position in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.